Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Sep 1:53:63-65.
doi: 10.1016/j.jdcr.2024.08.019. eCollection 2024 Nov.

Pityriasis rosea-like drug eruption secondary to deucravacitinib

Nisal Punchihewa  1   2 , Senhong Lee  1   3 , Chin-Guan Tan  4 , Peter Foley  1   2   5
Affiliations
Case Reports

Pityriasis rosea-like drug eruption secondary to deucravacitinib

Nisal Punchihewa et al. JAAD Case Rep. .
No abstract available

Keywords: cutaneous adverse reaction; deucravacitinib; drug rash; medical dermatology; pityriasis rosea.

PubMed Disclaimer

Conflict of interest statement

Dr Foley has received grant support, and/or served on advisory boards, and/or served as a consultant, and/or has received travel grants, and/or has served as a speaker for or received honoraria from AbbVie, Akaal, Amgen, Arcutis, Argenx, Aslan, AstraZeneca, Boehringer Ingelheim, Botanix, Bristol Myers Squibb, Celgene, Celtaxsys, CSL, Cutanea, Dermira, Evelo, Galderma, GenesisCare, Genentech, GlaxoSmithKline, Hexima, Incyte, Janssen, Kymab, Leo Pharma, Lilly, Mayne Pharma, MedImmune, Melaseq/Geneseq, Merck, Novartis, Pfizer, Regeneron, Reistone, Roche, Sanofi, SunPharma, Takeda, Teva, UCB Pharma, Valeant, and ZaiLab. Drs Punchihewa, Lee, and Tan have no conflicts of interest to declare.

Figures

Fig 1
Fig 1
Multiple erythematous papules coalescing to form plaques with collarettes of scale distributed over the upper limbs.
Fig 2
Fig 2
Close-up of the posterior thigh to highlight the collarette of scales.
Fig 3
Fig 3
Close-up of the forearm showing multiple erythematous papules with collarettes of scale.
Fig 4
Fig 4
Punch biopsy from the right forearm. Spongiosis with mounds of parakeratosis, perivascular lymphohistiocytic infiltrate, and red blood cell extravasation (hematoxylin and eosin, 50×, inset highlighting scattered eosinophils).
See this image and copyright information in PMC

References

    1. Strober B., Thaci D., Sofen H., et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023;88(1):40–51. doi: 10.1016/j.jaad.2022.08.061. - DOI - PubMed
    1. Chimalakonda A., Burke J., Cheng L., et al. Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with Janus kinase 1/2/3 inhibitors. Dermatol Ther (Heidelb) 2021;11(5):1763–1776. doi: 10.1007/s13555-021-00596-8. - DOI - PMC - PubMed
    1. Lebwohl M., Warren R.B., Sofen H., et al. Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials. Br J Dermatol. 2024;190(5):668–679. doi: 10.1093/bjd/ljae014. - DOI - PubMed
    1. Drago F., Broccolo F., Rebora A. Pityriasis rosea: an update with a critical appraisal of its possible herpesviral etiology. J Am Acad Dermatol. 2009;61(2):303–318. doi: 10.1016/j.jaad.2008.07.045. - DOI - PubMed
    1. Bitar C., Sadeghian A., Sullivan L., Murina A. Ibrutinib-associated pityriasis rosea-like rash. JAAD Case Rep. 2018;4(1):55–57. doi: 10.1016/j.jdcr.2017.06.035. - DOI - PMC - PubMed

Publication types

LinkOut - more resources